Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma

By afschroeder • July 26, 2025

Ribas A, Milhem MM, Hoimes CJ, Amin A, Lao CD, Conry RM, Hunt JP, Daniels GA, Almubarak M, Shaheen M, Medina T, Barve M, Bishnoi S, Abdi E, Chisamore MJ, Guiducci C, Gomez-Romo J, Candia A, Gamelin E, Coffman RL, Janssen RS, Long GV. Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma. Clin Cancer Res. 2025 Jul 25. doi: 10.1158/1078-0432.CCR-25-0987. Epub ahead of print. PMID: 40711475.

Tags: Hematology/Oncology, Publications

Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy

Carlson SG, Puliafito BR, Kawai K, Senaratne TN, Lee TD, Lin T, Timmerman J, Larson SM. Impact of clonal hematopoiesis of indeterminate potential on treatment[...]

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson[...]

Exploring Features of the Parasport Environment Associated With Quality Participation

Gee CM, Evans MB, Sinden AR, Shirazipour CH, Martin Ginis KA, Latimer-Cheung AE. Exploring Features of the Parasport Environment Associated With Quality Participation. Adapt Phys[...]